Neurocrine Biosciences, Inc. (NBIX)
| Market Cap | 15.94B +30.9% |
| Revenue (ttm) | 3.10B +28.6% |
| Net Income | 668.60M +118.6% |
| EPS | 6.50 +119.9% |
| Shares Out | 100.55M |
| PE Ratio | 24.53 |
| Forward PE | 14.27 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 260,133 |
| Open | 160.61 |
| Previous Close | 159.51 |
| Day's Range | 157.89 - 161.66 |
| 52-Week Range | 122.14 - 169.57 |
| Beta | 0.40 |
| Analysts | Strong Buy |
| Price Target | 192.88 (+21.71%) |
| Earnings Date | Jul 29, 2026 |
About NBIX
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical develo... [Read more]
Financial Performance
In 2025, Neurocrine Biosciences's revenue was $2.86 billion, an increase of 21.45% compared to the previous year's $2.36 billion. Earnings were $478.60 million, an increase of 40.23%.
Financial StatementsAnalyst Summary
According to 29 analysts, the average rating for NBIX stock is "Strong Buy." The 12-month stock price target is $192.88, which is an increase of 21.71% from the latest price.
News
Soleno Therapeutics presents new VYKAT XR data at ENDO 2026
Soleno Therapeutics, a Neurocrine (NBIX) Biosciences company, announced late-breaking data at ENDO 2026 showing that resuming treatment with VYKAT XR extended-release tablets for two years after a 16-...
Neurocrine presents first retrospective case series of Crenessity
Neurocrine (NBIX) Biosciences announced clinical findings from the first retrospective case series in pediatric and adult patients with classic congenital adrenal hyperplasia due to 11beta-hydroxylase...
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period
Participants who resumed VYKAT XR following a 16-week randomized withdrawal period demonstrated improvements in hyperphagia and behavioral symptoms as early as Week 13, with benefits continuing throug...
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
Androstenedione and other adrenal hormone levels in 11β‑hydroxylase-deficient patients improved substantially after initiation of CRENESSITY, with >90% median reductions in 11-deoxycortisol and 11-deo...
Neurocrine presents two-year Crenessity data
Neurocrine (NBIX) Biosciences announced new Phase 3 CAHtalyst Adult study data demonstrating improved cardiometabolic outcomes alongside sustained glucocorticoid dose reduction through up to two years...
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026
Two-year data showed that pediatric patients with accelerated bone age at baseline experienced slowed bone age progression and improved predicted adult height with CRENESSITY Cross-sectional caregiver...
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026
Two-year CRENESSITY data in adults showed improvements in cardiometabolic outcomes of insulin resistance, body composition and body weight alongside sustained reductions in glucocorticoid dose Among p...
Neurocrine Biosciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company has evolved into a multi-product leader with strong revenue growth from INGREZZA, CRENESSITY, and VYKAT XR, supported by strategic acquisitions and a robust R&D pipeline. Key pipeline assets are set for major data readouts in 2027–2028, while ongoing investments in sales force and market education drive adoption and future growth.
Neurocrine reports new post-hoc data from KINECT 4 trial
Neurocrine (NBIX) Biosciences announced new post-hoc data from the KINECT 4 clinical trial demonstrating that adults with tardive dyskinesia treated with INGREZZA capsules experienced clinically meani...
Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients
New 48-week KINECT® 4 post-hoc analysis shows 94% of participants treated with INGREZZA achieved either symptomatic remission or a clinically meaningful response (≥30% reduction from baseline in Abnor...
Neurocrine presents new data showing Improvements with INGREZZA
Neurocrine (NBIX) Biosciences announced new clinician-reported data in patients with intellectual and developmental disabilities demonstrating meaningful and rapid improvements in tardive dyskinesia s...
Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities
Nearly all individuals with intellectual and developmental disabilities experienced improvement in tardive dyskinesia severity after starting INGREZZA, and of those, 89% experienced improvement within...
Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026
Analyses span adult and pediatric populations with classic congenital adrenal hyperplasia (CAH) and reflect longer-term clinical outcomes relevant to disease management across lifespan and care contin...
Neurocrine Biosciences Transcript: 46th Annual William Blair Growth Stock Conference
Significant transformation to a multi-product, high-growth company with strong cash flow and diversified revenue. Recent acquisition of Soleno Therapeutics expands the rare endocrine franchise, while robust R&D investment supports a broad pipeline and future growth.
Neurocrine reinstated with a Buy at Goldman Sachs
Goldman Sachs reinstated coverage of Neurocrine (NBIX) with a Buy rating and $213 price target The completion of the Soleno Therapeutics acquisition bolsters the company’s medium-term revenue growth t...
Neurocrine price target raised to $183 from $180 at RBC Capital
RBC Capital raised the firm’s price target on Neurocrine (NBIX) to $183 from $180 and keeps an Outperform rating on the shares. Shares have rebounded following a strong Q1, though…
Neurocrine Biosciences to Present at Upcoming Investor Conferences in June
SAN DIEGO, May 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences: William Blair 46 th Annu...
Neurocrine initiated with Outperform at Bernstein on long runway of key drugs
Bernstein analyst Jeffrey Walch initiated coverage of Neurocrine (NBIX) with an Outperform rating and $221 price target The firm sees the company as one of the more promising investments within…
Neurocrine initiated with an Outperform at Bernstein
Bernstein analyst Jeffrey Walch initiated coverage of Neurocrine (NBIX) with an Outperform rating and $221 price target
Neurocrine announces new data from a clinician survey in Ingrezza
Neurocrine (NBIX) Biosciences announced the presentation of new data from a clinician survey highlighting the functional impact experienced by patients with mild tardive dyskinesia, or TD, severity an...
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules
Clinician survey showed 90% of patients with mild tardive dyskinesia experienced emotional, social or physical impairment Following initiation of INGREZZA, 96% of patients with mild tardive dyskinesia...
Neurocrine completes acquisition of Soleno Therapeutics
Neurocrine Biosciences (NBIX) announced the completion of its acquisition of Soleno Therapeutics (SLNO), strengthening the company’s leadership in endocrinology and rare disease. As of May 18, Soleno’...
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
Strengthens Neurocrine's rare disease portfolio with VYKAT™ XR, the first and only approved treatment for hyperphagia in Prader-Willi syndrome Adds recently launched therapy with strong early adoption...
4basebio Announces Appointment of Chief Financial Officer and Board Changes
Richard Bungay appointed as CFO, bringing a strong track record in fundraising, M&A and partnering for listed and private companies, including two major exits and over $400m raised Cambridge, UK, 14 M...
Neurocrine Biosciences Transcript: Bank of America Global Healthcare Conference 2026
Strong Q1 performance was driven by INGREZZA, CRENESSITY, and the addition of VYKAT XR, with all products showing durable growth and long patent protection. The pipeline is robust, with key phase III readouts expected in 2027–2028, and the Soleno acquisition is immediately accretive.